This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ray, A. S. Articles by Anderson, K. S. Search for Related Content PubMed PubMed Citation Articles by Ray, A. S. Articles by Anderson, K. S.

Mechanism of Anti-Human Immunodeficiency Virus Activity of ß-D-6-Cyclopropylamino-2',3'-Didehydro-2',3'-Dideoxyguanosine

Department of Pharmacology, Yale University School of Medicine, New Haven Connecticut 06520-8066,¹ Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine/VAMC, Decatur, Georgia 30033,² Department of Pharmacology and Biomedical Sciences, College of Pharmacy, The University of Georgia, Athens, Georgia 30602-2352,³ Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 30322⁴

Received 2 July 2004/ Returned for modification 7 October 2004/ Accepted 5 January 2005

To better understand the importance of the oxygen in the ribose ring of planar unsaturated nucleoside analogs that target human immunodeficiency virus (HIV), a 6-cyclopropyl-substituted prodrug of 2',3'-didehydro-2',3'-dideoxyguanosine (cyclo-d4G) was synthesized, and its cellular metabolism, antiviral activity, and pharmacokinetic behavior were studied. Cyclo-d4G had selective anti-HIV activity in primary blood mononuclear cells (PBMCs), effectively inhibiting the LAI strain of HIV-1 by 50% at 1.1 ± 0.1 µM while showing 50% inhibition of cell viability at 84.5 µM. The antiviral activity in PBMCs was not markedly affected by mutations of methionine to valine at position 184 or by thymidine-associated mutations in the viral reverse transcriptase. Mutations of leucine 74 to valine and of lysine 65 to arginine had mild to moderate resistance (as high as fivefold). Studies to delineate the mechanism of cellular metabolism and activation of cyclo-d4G showed reduced potency in inhibiting viral replication in the presence of the adenosine/adenylate deaminase inhibitor 2'-deoxycoformycin, implying that the antiviral activity is due to its metabolism to the 2'-dGTP analog d4GTP. Intracellular formation of sugar catabolites illustrates the chemical and potentially enzymatic instability of the glycosidic linkage in d4G. Further studies suggest that cyclo-d4G has a novel intracellular phosphorylation pathway. Cyclo-d4G had a lower potential to cause mitochondrial toxicity than 2',3'-dideoxycytidine and 2',3'-didehydro-3'-deoxythymidine in neuronal cells. Also, cyclo-d4G had advantageous synergism with many currently used anti-HIV drugs. Poor oral bioavailability observed in rhesus monkeys may be due to the labile glycosidic bond, and special formulation may be necessary for oral delivery.